Country: European Union
Language: English
Source: EMA (European Medicines Agency)
aliskiren
Noden Pharma DAC
C09XA02
aliskiren
Agents acting on the renin-angiotensin system
Hypertension
Treatment of essential hypertension.
Revision: 27
Authorised
2007-08-22
40 B. PACKAGE LEAFLET 41 PACKAGE LEAFLET: INFORMATION FOR THE USER RASILEZ 150 MG FILM-COATED TABLETS RASILEZ 300 MG FILM-COATED TABLETS Aliskiren READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Rasilez is and what it is used for 2. What you need to know before you take Rasilez 3. How to take Rasilez 4. Possible side effects 5. How to store Rasilez 6. Contents of the pack and other information 1. WHAT RASILEZ IS AND WHAT IT IS USED FOR This medicine contains an active substance called aliskiren. Aliskiren belongs to a class of medicines called renin inhibitors. Renin inhibitors reduce the amount of angiotensin II the body can produce. Angiotensin II causes blood vessels to tighten, which increases the blood pressure. Reducing the amount of angiotensin II allows the blood vessels to relax, which lowers blood pressure. This helps to lower high blood pressure in adult patients. High blood pressure increases the workload of the heart and arteries. If this continues for a long time, it can damage the blood vessels of the brain, heart and kidneys, and may result in a stroke, heart failure, heart attack or kidney failure. Lowering the blood pressure to a normal level reduces the risk of developing these disorders. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE RASILEZ DO NOT TAKE RASILEZ - if you are allergic to aliskiren or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice. - if you have experienced the following forms of angioe Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Rasilez 150 mg film-coated tablets Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). Rasilez 300 mg film-coated tablets Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Rasilez 150 mg film-coated tablets Light-pink, biconvex, round tablet, imprinted “IL” on one side and “NVR” on the other side. Rasilez 300 mg film-coated tablets Light-red, biconvex, ovaloid tablet, imprinted “IU” on one side and “NVR” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the dose may be increased to 300 mg once daily. The antihypertensive effect is substantially present within two weeks (85-90%) after initiating therapy with 150 mg once daily. Rasilez may be used alone or in combination with other antihypertensive agents with the exception of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) < 60 ml/min/1.73 m 2 ) (see sections 4.3, 4.4 and 5.1). _Special populations _ _ _ _Renal impairment _ No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Aliskiren is not recommended in patients with severe renal impairment (GFR < 30 ml/min/1.73 m 2 ). 3 _Hepatic impairment _ No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see section 5.2). _Elderly patients aged 65 years and over_ The recommended starting Read the complete document